No Data
Sansure Biotech Inc.'s (SHSE:688289) Largest Shareholder, CEO Lizhong Dai Sees Holdings Value Fall by 3.4% Following Recent Drop
Sansure Biotech's H1 Attributable Profit Surges 71%; Shares Fall 3%
Full text of Sansure Biotech Inc.'s 2024 interim report
Summary of Sansure Biotech Inc.'s 2024 half-yearly report.
Sansure Biotech Inc. (688289.SH) released its performance report for the first half of the year, with net income of 0.157 billion yuan, a year-on-year increase of 70.93%. It plans to distribute 2.50 yuan per 10 shares.
Sansure Biotech Inc. (688289.SH) released its 2024 interim report, achieving a revenue of 7... during the reporting period.
Sansure Biotech Gets Nod to Register ApoE Gene Detection Kit
No Data
